The company said, “Tempus increased full year 2025 revenue guidance to approximately $1.265 billion, which represents ~80% annual growth. Given the acquisition of Paige, which we expect will increase losses by approximately $5 million per quarter, we expect Q4 Adjusted EBITDA to be ~$20 million, resulting in slightly positive Adjusted EBITDA for the full year.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI’s Strategic Collaboration with Whitehawk Therapeutics Bolsters Buy Rating with Promising Oncology Advances
- Cathie Wood Trims Exposure to AMD and Other U.S. Tech Favorites, Doubles Down on Baidu and Biotech Plays
- Guardant Health price target raised to $90 from $60 at Piper Sandler
- Tempus AI price target raised to $105 from $70 at Piper Sandler
- Goldman downgraded, Coinbase initiated: Wall Street’s top analyst calls